|
1
|
Oved JH, Lee CS and Bussel JB: Treatment
of children with persistent and chronic idiopathic thrombocytopenic
purpura: 4 infusions of rituximab and three 4-day cycles of
dexamethasone. J Pediatr. 191:225–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takase K, Kada A, Iwasaki H, Yoshida I,
Sawamura M, Yoshio N, Yoshida S, Iida H, Otsuka M, Takafuta T, et
al: High-dose dexamethasone therapy as the initial treatment for
idiopathic thrombocytopenic purpura: Protocol for a multicenter,
open-label, single arm trial. Acta Med Okayama. 72:197–201.
2018.PubMed/NCBI
|
|
3
|
Zhao CH and Hou M: Advances of research on
abnormality of cell immunity in idiopathic thrombocytopenic
purpura: Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 14:1045–1048.
2006.(In Chinese). PubMed/NCBI
|
|
4
|
Chandan JS, Thomas T, Lee S, Marshall T,
Willis B, Nirantharakumar K and Gill P: The association between
idiopathic thrombocytopenic purpura and cardiovascular disease: A
retrospective cohort study. J Thromb Haemost. 16:474–480. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wasserman RL: Gammaplex® 5 and
10% in the treatment of primary immunodeficiency and chronic immune
thrombocytopenic purpura. Immunotherapy. 9:1071–1088. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Niscola P, Scaramucci L and Giovannini M:
Spleen tyrosine kinase inhibition: A new promising approach to
chronic and refractory immune thrombocytopenia. Immunotherapy.
10:5–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vendramin C, Thomas M, Westwood JP,
McGuckin S and Scully M: Rituximab-induced acute and delayed serum
sickness in thrombotic thrombocytopenic purpura: The role of
anti-rituximab antibodies. Br J Haematol. Mar 12–2018.(Epub ahead
of print). doi: 10.1111/bjh.15177. View Article : Google Scholar
|
|
8
|
Martinez AR, Paul MR and Kuo DJ: Treatment
of immune thrombocytopenic purpura associated with cytomegalovirus
infection in a child with pre-B cell acute lymphoblastic leukaemia
after central nervous system relapse. BMJ Case Rep. 2017(pii):
bcr-2017-221947. 2017.
|
|
9
|
Page EE, Kremer Hovinga JA, Terrell DR,
Vesely SK and George JN: Thrombotic thrombocytopenic purpura:
Diagnostic criteria, clinical features, and long-term outcomes from
1995 through 2015. Blood Adv. 1:590–600. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Molineux G and Newland A: Development of
romiplostim for the treatment of patients with chronic immune
thrombocytopenia: From bench to bedside. Br J Haematol. 150:9–20.
2010.PubMed/NCBI
|
|
11
|
Chowdhry M, Makroo RN, Thakur Y, Agrawal
S, Mishra M and Rani D: Hyperheptaploidy in idiopathic
thrombocytopenic purpura. Indian J Pathol Microbiol. 61:161–162.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kubota M, Usami I, Kobayashi K, Tsutsui T
and Matsubara K: Serum immunoglobulin levels at onset: Association
with the prognosis of childhood idiopathic thrombocytopenic
purpura. Int J Hematol. 77:304–307. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raheja H, Kumar V, Hollander G, Shani J
and Greenberg Y: Intravenous immunoglobulin-induced profound
bradycardia in a patient with idiopathic thrombocytopenic purpura.
Am J Ther. 25:e572–e574. 2018.PubMed/NCBI
|
|
14
|
Rezaeeyan H, Jaseb K, Alghasi A, Asnafi AA
and Saki N: Association between gene polymorphisms and clinical
features in idiopathic thrombocytopenic purpura patients. Blood
Coagul Fibrinolysis. 28:617–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peyvandi F, Scully M, Kremer Hovinga JA,
Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H and
Zeldin RK: Caplacizumab reduces the frequency of major
thromboembolic events, exacerbations and death in patients with
acquired thrombotic thrombocytopenic purpura. J Thromb Haemost.
15:1448–1452. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Payandeh M, Sohrabi N, Zare ME, Kansestani
AN and Hashemian AH: Platelet count response to Helicobacter
pylori eradication in Iranian patients with idiopathic
thrombocytopenic purpura. Mediterr J Hematol Infect Dis.
4:e20120562012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shoukat BA, Ali O, Kumar D, Bilal Gilani
M, Zahid A, Aslam Joiya S and Anwar Malik M: Hypogammaglobulinemia
observed one year after rituximab treatment for idiopathic
thrombocytopenic purpura. Case Rep Med. 2018:20961862018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warner NC, Vaughan LB and Wenzel RP: Human
immunodeficiency virus associated thrombotic thrombocytopenic
purpura, a clinical conundrum. J Clin Apher. 32:567–570. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gödel P, Fischer J, Scheid C, Gathof BS,
Wolf J and Rybniker J: Familial acquired thrombotic
thrombocytopenic purpura in siblings - no immunogenetic link with
associated human leucocyte antigens. Eur J Haematol. 98:311–313.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rashid RM, Nabi Z, Ansari AZ and Qaiser
QA: Immune thrombocytopenic purpura presenting in a patient after
renal transplant for diabetic nephropathy. BMC Nephrol. 19:692018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duperier T, Brody F, Felsher J, Walsh RM,
Rosen M and Ponsky J: Predictive factors for successful
laparoscopic splenectomy in patients with immune thrombocytopenic
purpura. Arch Surg. 139:61–66. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Al Askar AS, Shaheen NA, Al Zahrani M, Al
Otaibi MG, Al Qahtani BS, Ahmed F, Al Zughaibi M, Kamran I, Mendoza
MA and Khan A: Splenectomy vs. rituximab as a second-line therapy
in immune thrombocytopenic purpura: A single center experience. Int
J Hematol. 107:69–74. 2018. View Article : Google Scholar : PubMed/NCBI
|
